Rifaximin is a Bioavailability, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. It is based on the rifamycin antibiotics family. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of non-infectious gastrointestinal diseases like irritable bowel syndrome and hepatic encephalopathy. It acts by inhibiting RNA synthesis in susceptible bacteria by binding to the RNA polymerase enzyme. This binding blocks translocation, which stops transcription.
Medical uses
Travelers' diarrhea
Rifaximin is used to treat travelers' diarrhea caused by
Escherichia coli bacteria in people aged twelve years of age and older. It treats travelers' diarrhea by stopping the growth of the bacteria that cause diarrhea. Rifaximin will not work to treat travelers' diarrhea that is bloody or occurs with fever.
Irritable bowel syndrome
Rifaximin is used for the treatment of irritable bowel syndrome (IBS). It possesses anti-inflammatory and antibacterial properties, and is a non-absorbable antibiotic that acts locally in the gut. These properties make it efficacious in relieving chronic functional symptoms of non-
constipation type irritable bowel syndrome.
It appears to retain its therapeutic properties for this indication, even after repeated courses.
It is particularly indicated where small intestine bacterial overgrowth is suspected of involvement in irritable bowel syndrome. Symptom relief or improvement can be obtained for global irritable bowel syndrome symptoms, including: abdominal pain,
flatulence,
bloating, and
Feces consistency. A drawback is that repeated courses may be necessary for remission of symptoms.
Clostridioides difficile infection
Rifaximin may also be a useful addition to
vancomycin when treating people with relapsing
C. difficile infection.
However, the quality of evidence of these studies was judged to be low.
Because exposure to rifamycins in the past may increase risk for resistance, rifaximin should be avoided in such cases.
Hepatic encephalopathy
Rifaximin is used to prevent episodes of hepatic encephalopathy (changes in thinking, behavior, and personality caused by a build-up of toxins in the brain in adults who have liver disease). It treats hepatic encephalopathy by stopping the growth of bacteria that produce toxins and that may worsen the liver disease. Although high-quality evidence is lacking, it appears to be as effective as, or more effective than, other available treatments for hepatic encephalopathy (such as
lactulose), is better tolerated, and may work faster.
[ Free full text with registration at Medscape.] It prevents reoccurring encephalopathy and is associated with high patient satisfaction. People are more compliant and satisfied to take this medication than any other due to minimal side effects, prolonged remission, and overall cost.
The drawbacks are increased cost, and lack of robust clinical trials for hepatic encephalopathy without combination lactulose therapy.
Other uses
Other uses include treatment of: infectious diarrhea, small intestinal bacterial overgrowth, inflammatory bowel disease, and diverticular disease.
It is effective in treating small intestinal bacterial overgrowth regardless of whether it is associated with irritable bowel syndrome or not.
It has also shown efficacy with
rosacea, ocular rosacea which also presents as
dry eyes for patients with co-occurrence with small intestinal bacterial overgrowth (SIBO).
Veterinary uses
Rifaximin is used to treat cattle mastitis intramammarily and post-partum metritis intrauterinally.
Special caution
People should avoid rifaximin if they are allergic either
rifabutin, rifampin, or
rifapentine. It may cause attenuated vaccines (such as typhoid vaccine) not to work well. Health-care professionals should be informed about its usage before giving
.
Pregnant or breastfeeding women should avoid rifaximin: it can harm the
fetus.
Caution is required in people with
cirrhosis who have a Child–Pugh score of C.
Side effects
Rifaximin has an excellent safety profile due to its lack of systemic absorption. Clinical trials did not show any serious adverse events while using rifaximin. There were no deaths while using it in the clinical trials.
The most common side effects include nausea, Abdominal pain, dizziness, fatigue, headaches, muscle tightening, and Arthralgia. It may also cause reddish discoloration of urine.
The most serious side effects of rifaximin are:
-
Clostridioides difficile-associated diarrhea
-
Drug-resistant bacterial superinfection
-
Severe allergic reactions including hives, and
Interactions
As rifaximin is not significantly absorbed from the gut, the great majority of this drug's interactions are negligible in people with healthy liver function, so healthcare providers usually do not worry about drug interactions unless liver impairment is present.
It may decrease the effectiveness of
warfarin, a commonly prescribed anticoagulant, in people with liver problems.
Pharmacology
Rifaximin is a
semisynthetic broad spectrum antibacterial drug, derived through chemical modification of the natural antibiotic
rifamycin.
It has very low
bioavailability due to its poor absorption after oral administration. Because of this local action within the gut and the lack of horizontal transfer of resistance genes, the development of bacterial resistance is rare, and most of the drug taken orally stays in the gastrointestinal tract where the infection takes place.
Mechanism of action
Rifaximin interferes with transcription by binding to the β-subunit of bacterial
RNA polymerase.
This results in the blockage of the translocation step that normally follows the formation of the first phosphodiester bond, which occurs in the transcription process.
This in turn results in a reduction of bacteria populations, including gas-producing bacteria, which may reduce
mucosal inflammation,
epithelial dysfunction, and visceral hypersensitivity. Rifaximin has broad spectrum antibacterial properties against both
gram positive and
gram negative anaerobic and
aerobic bacteria. As a result of
bile acid solubility, its antibacterial action is limited mostly to the
small intestine and less so the
Large intestine.
A resetting of the bacterial composition has also been suggested as a possible mechanism of action for relief of irritable bowel syndrome symptoms.
Additionally, rifaximin may have a direct anti-inflammatory effect on gut mucosa via modulation of the pregnane X receptor.
Other mechanisms for its therapeutic properties include inhibition of bacterial translocation across the epithelial lining of the
intestine, inhibition of adherence of bacteria to the
epithelial cells, and a reduction in the expression of proinflammatory cytokines.
Availability
In the United States, Salix Pharmaceuticals holds a US Patent for rifaximin and markets it under the brand name Xifaxan.
In addition to receiving FDA approval for travelers' diarrhea and (marketing approved for)
hepatic encephalopathy, rifaximin received FDA approval for irritable bowel syndrome in May 2015.
No generic formulation is available in the US and none has appeared due to the fact that the FDA approval process was ongoing. If rifaximin receives full FDA approval for hepatic encephalopathy it is likely that Salix will maintain marketing exclusivity and be protected from generic formulations until 24 March 2017.
In 2018, a patent dispute with Teva was settled which delayed a generic in the United States, with the patent set to expire in 2029.
Rifaximin is approved in many countries for the treatment of certain gastrointestinal disorders.
Physicochemical properties
Rifaximin can exist in different crystalline forms depending on the degree of
Hydration number. They drastically differ in water solubility, which has to be taken into account during the manufacturing process.
Wet rifaximin exists in the β-form, which can be dehydrated to obtain forms α and δ. ε-Form can be only obtained by dehydrating δ-form. Amongst them, γ-form is the most stable and is resistant to high humidity levels.
Based upon animal-model studies,
bioavailability (C
max, t
max, AUC
0-24, AUC
∞) increases in the following order: β, α, ε, δ, γ.
Thus, structures with lower bioavailability exert their antimicrobial activity more locally in the gastrointestinal tract, whereas δ- and γ-forms are more suitable for systemic treatment
(however the problem with cross-resistance with rifampicin in
Mycobacterium tuberculosis might lead to multidrug-resistant strain selection
).
